NCT07866326 Prevalence of Adrenal Insufficiency and Associated Factors in Rheumatoid Arthritis Patients Using Low-dose Corticosteroids.
| NCT ID | NCT07866326 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Bursa Yuksek Ihtisas Training and Research Hospital |
| Condition | Reumatoid Arthritis |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2026-07-31 |
| Primary Completion | 2027-07-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2026-07-31 with a primary completion date of 2027-07-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to investigate the prevalence of adrenal insufficiency in rheumatoid arthritis (RA) patients receiving low-dose corticosteroid therapy and to identify the factors influencing adrenal insufficiency. To this end, the researchers plan to conduct a study comparing the prevalence of adrenal insufficiency and associated factors among RA patients-who are currently receiving low-dose corticosteroid therapy during outpatient follow-up and have consented to participate-by categorizing them into three groups based on the duration of treatment: short (3 weeks-3 months), medium (3-12 months), and long (\>12 months).
Eligibility Criteria
Inclusion Criteria: * Participants diagnosed with rheumatoid arthritis according to the 2010 ACR/EULAR criteria. * Participants who have been undergoing corticosteroid treatment for at least 3 weeks. * Participants in remission or with low disease activity (DAS28-CRP ≤3.2). Exclusion Criteria: * Patients with primary adrenal insufficiency. * Participants who have received pulse steroid therapy within the last 6 months. * Pregnancy and lactation. * Hypopituitarism * Uncontrolled diabetes mellitus * Comorbidities; ≥NYHA Class 3 heart failure, Stage 3 chronic kidney failure, ≥Child-Pugh Class B liver cirrhosis
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07866326 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Reumatoid Arthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07866326 currently recruiting?
Yes, NCT07866326 is actively recruiting participants. Contact the research team at ayarkoray@hotmail.com for enrollment information.
Where is the NCT07866326 trial being conducted?
This trial is being conducted at Bursa, Turkey (Türkiye).
Who is sponsoring the NCT07866326 clinical trial?
NCT07866326 is sponsored by Bursa Yuksek Ihtisas Training and Research Hospital. The trial plans to enroll 120 participants.